110.93
-2.28 (-2.01%)
| Previous Close | 113.21 |
| Open | 114.07 |
| Volume | 808,430 |
| Avg. Volume (3M) | 896,919 |
| Market Cap | 3,831,983,616 |
| Price / Earnings (TTM) | 22.78 |
| Price / Earnings (Forward) | 40.16 |
| Price / Sales | 6.70 |
| Price / Book | 7.30 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.42 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 175.00 (Oppenheimer, 57.76%) | Buy |
| Median | 165.00 (48.74%) | |
| Low | 130.00 (Stifel, 17.19%) | Hold |
| Average | 159.67 (43.94%) | |
| Total | 4 Buy, 2 Hold | |
| Avg. Price @ Call | 132.34 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 09 Mar 2026 | 130.00 (17.19%) | Hold | 134.77 |
| Evercore ISI Group | 25 Feb 2026 | 170.00 (53.25%) | Buy | 131.85 |
| JP Morgan | 25 Feb 2026 | 149.00 (34.32%) | Hold | 131.85 |
| Needham | 25 Feb 2026 | 174.00 (56.86%) | Buy | 131.85 |
| Oppenheimer | 25 Feb 2026 | 175.00 (57.76%) | Buy | 131.85 |
| Piper Sandler | 25 Feb 2026 | 160.00 (44.24%) | Buy | 131.85 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |